| CAS NO: | 745-65-3 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 354.48 |
| Cas No. | 745-65-3 |
| Formula | C20H34O5 |
| Solubility | insoluble in H2O; ≥13.4 mg/mL in DMSO; ≥47.1 mg/mL in EtOH |
| Chemical Name | 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid |
| Canonical SMILES | CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Cell experiment:[1] | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Reaction Conditions | 0 ~ 10 μM alprostadil |
Applications | Alprostadil (1 nM ~ 10 μM; 48 h) concentration-dependently reduced HUVEC proliferation (up to 100% inhibition) in the presence of 20 ng/mL vascular endothelial growth factor (VEGF), with an IC50 of 400 nM. Alprostadil (0.01 ~ 10 μM; 6 h) also inhibited VEGF-induced HUVEC migration in a concentration dependent manner, with an IC50 of 500 nM. |
| Animal experiment:[1] | |
Animal models | Female C57/bl6 mice, 6 ~ 8 weeks of age |
Dosage form | 20 ng Administered subcutaneously for 4 days |
Applications | Alprostadil treatment (20 ng/animal/day; 4 days) significantly inhibited the fibroblast growth factor (FGF)-induced angiogenesis in mice. Alprostadil could be useful for diseases that require anti-angiogenic therapy, such as diabetic retinopathy and solid tumors. |
Note | The technical data provided above is for reference only. |
References: 1. Cattaneo MG, Pola S, Dehò V, et al. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. British Journal of Pharmacology, 2003, 138(2): 377-385. | |
m.cnreagent.com